Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit

By Bryan Koenig · August 28, 2024, 7:33 PM EDT

Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In re Xyrem (Sodium Oxybate) Antitrust Litigation

Case Number

3:20-md-02966

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

December 16, 2020

Featured Stories

What Del. Legal Leaders Are Thinking About Heading Into '25 No Photo Available

Rose Krebs

Figuring out how to best use generative tools in the practice of law, attracting and retaining talent in a competitive legal market, m... (more story)

Auto Supply Chain Susceptible To Tariff-Fueled Bankruptcies No Photo Available

Vince Sullivan

Tariffs suggested by President-elect Donald J. Trump would hit an already precariously-positioned North American auto industry particu... (more story)

Healthcare Restructuring Trends To Watch In 2025 No Photo Available

Ben Zigterman

With bankruptcy filings from the likes of hospital operator Steward Health Care, nursing home company Petersen Health and ventilator p... (more story)